Autopsy report · NCT00557622

Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)

“difficulty in achieving target enrollment numbers”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 11 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Post-Traumatic Stress Disorder; Stress Disorders, Post-Traumatic

Interventions

paroxetine; placebo

Participants

5

Sites

9

Countries

Japan

Trials that died the same way

• Comparison of Rectal Trumpet and Standard Care
  “Unable to recruit target enrollment numbers” (85% match in meaning)
• Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
  “unable to meet the target enrollment goal” (76% match in meaning)
• Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss
  “difficulty in enrollment” (75% match in meaning)
• Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease
  “Difficulty with enrollment” (74% match in meaning)
• Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
  “Insufficient resources to meet enrollment target” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.